GlassScriptPhysician profile
Katherine Lietz
NPI 1194864157
$1,869.35
in general payments reported to CMS, 2019-2025
20 companies · $647 in 2025
The $647 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $31.82 · 2021: $146 · 2022: $241 · 2023: $409 · 2024: $221 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,278.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $468.44 | 2024-2025 | Barostim Neo System |
| Abiomed | $378.60 | 2024-2025 | Impella |
| Abbott Laboratories | $354.24 | 2022-2023 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $183.34 | 2019-2023 | Lifevest |
| Merck Sharp & Dohme LLC | $70.19 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $64.16 | 2022-2023 | Optimizer |
| Novartis Pharmaceuticals Corporation | $54.04 | 2019-2022 | |
| Vifor Pharma, INC. | $46.63 | 2019 | |
| Alnylam Pharmaceuticals INC. | $36.15 | 2019-2021 | |
| United Therapeutics Corporation | $25.81 | 2023 | Remodulin |
| Genzyme Corporation | $24.99 | 2023 | |
| Bridgebio Pharma, INC. | $21.84 | 2025 | Attruby |
| Medtronic Vascular, INC. | $21.22 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.98 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $18.35 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $18.16 | 2020 | |
| Atricure, INC. | $17.28 | 2019 | |
| Sandoz INC. | $16.75 | 2023 | Treprostinil |
| Pfizer INC. | $15.20 | 2019 | |
| Amgen INC. | $12.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Lietz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.